TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.
about
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational researchVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Long-term outcomes of helper peptide vaccination for metastatic melanoma.Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing miceBiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.Virus-like particles for the prevention of human papillomavirus-associated malignancies.Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.Immunologic treatments for precancerous lesions and uterine cervical cancer.The road ahead for cervical cancer prevention and control.The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity.Designing therapeutic cancer vaccines by mimicking viral infections.DNA-based immunotherapy for HPV-associated head and neck cancer.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.Cancer immunotherapy: moving forward with peptide T cell vaccines.A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway.Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.Effective antitumor peptide vaccines can induce severe autoimmune pathology.Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.CD70 encoded by modified vaccinia virus Ankara enhances CD8 T cell dependent protective immunity in MHC class II-deficient mice.Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.Emerging human papillomavirus vaccines
P2860
Q26744094-DC959FF7-5B42-45DF-8EA8-15923DE1D31BQ26796314-B757A2C9-55B0-4CCE-A760-FBB75BBD9FD1Q30278874-5638E1F3-5214-45B4-8881-F97ECFF84C5DQ35013272-B34D7E17-B1C3-46AA-8067-38B6BCF1389BQ35864569-26C13F38-4B2C-43ED-81AE-F599A700BCB1Q36288074-7080BD49-4793-4DB2-86D5-29E545CE38BBQ36763266-2B61A4E9-1310-48A0-AB0B-A79CA337C2EFQ37328475-6CF3BE95-C7C7-4003-841A-2AE2F7078988Q37641401-0ED0A0F5-E9AC-4F78-B096-AFD2D48B563CQ37703113-644781C5-0E2B-467F-8C94-D5DB422342ECQ37719631-B6307651-8CD1-42F8-9468-BDAA6AE63D3BQ38254337-9B9D03F5-EBC0-4F5C-8468-1DE62BFE436DQ38648043-1DD83EB3-73C9-4657-BA57-BD70D1A5C8DCQ38800011-32BA6D5E-FB27-4F63-A8D9-EC15564EFB3EQ38948889-1D538B79-76CD-45EF-9CB1-095FF77822AAQ38948897-2B3CA3FB-F302-4C16-86D4-2A038C209BB3Q39451757-637BD973-6477-4A29-BF01-8BF93BA9AB21Q40877648-651967C0-D13D-42CF-89D3-A3893DA5F554Q42273331-985B77AD-A3DC-4D12-842D-21C0C63A9F46Q42378431-A3934FE2-4D10-45A9-992D-1184D310C45DQ47162004-4FF0F23B-9634-4874-9C4E-B669E305735CQ47242631-558DF752-2A49-4AAD-8D44-AC58613EA101Q52684506-A9F68DB5-542B-4837-8BD0-3C15377865BDQ56967486-5C043504-F77D-4BD0-94BB-0CD4DD6BBE92
P2860
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
TriVax-HPV: an improved peptid ...... apillomavirus-induced cancers.
@ast
TriVax-HPV: an improved peptid ...... apillomavirus-induced cancers.
@en
type
label
TriVax-HPV: an improved peptid ...... apillomavirus-induced cancers.
@ast
TriVax-HPV: an improved peptid ...... apillomavirus-induced cancers.
@en
prefLabel
TriVax-HPV: an improved peptid ...... apillomavirus-induced cancers.
@ast
TriVax-HPV: an improved peptid ...... apillomavirus-induced cancers.
@en
P2860
P1476
TriVax-HPV: an improved peptid ...... apillomavirus-induced cancers.
@en
P2093
Esteban Celis
Kelly Barrios
P2860
P2888
P304
P356
10.1007/S00262-012-1259-8
P577
2012-04-22T00:00:00Z